C4 THERAPEUTICS INC (CCCC)

US12529R1077 - Common Stock

6.43  -0.11 (-1.68%)

After market: 6.61 +0.18 (+2.8%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
45.79M
37.92%		31.1M
-32.08%		20.756M
-33.26%		27.37M
31.87%
EBITDA
YoY % growth
-80.64M
-37.07%		-127.85M
-58.54%		-137.151M
-7.27%		-111.617M
18.62%		N/AN/AN/AN/A
EBIT
YoY % growth
-82.13M
-35.86%		-129.53M
-57.71%		-139.031M
-7.33%		-133.763M
3.79%
Operating Margin
-179.36%-416.50%-669.84%-488.72%
EPS
YoY % growth
-1.82-2.63
-44.51%		-2.66
-1.14%		-1.89
29.10%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.36
49.51%
Revenue
Q2Q % growth		8.262M
119.73%
EBITDA
Q2Q % growth		-24.613M
EBIT
Q2Q % growth		-29.09M
19.71%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.70
9.09%		-0.700.00-0.55%
Q3 2023
Q2Q % growth		 -0.52
20.00%		-0.670.1522.76%
Q2 2023
Q2Q % growth		 -0.73
-30.36%		-0.70-0.03-4.06%
Q1 2023
Q2Q % growth		 -0.71
-9.23%		-0.760.056.66%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 3.261M
14.42%		3.253M8K0.25%
Q3 2023
Q2Q % growth		 11.072M
64.03%		5.569M5.503M98.81%
Q2 2023
Q2Q % growth		 2.66M
-80.77%		6.568M-3.908M-59.50%
Q1 2023
Q2Q % growth		 3.76M
-50.85%		5.572M-1.812M-32.52%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 34.31% 0% 18.63%
Revenue0% N/A 0% 37.83%